Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.41 |
| ▸ | GPR6 | P46095 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229179 | 0.85 | CHRM4 (0.45) | CHRM4GPR6 | |
| SCHEMBL30529023 | 0.85 | CCR1 (0.45) | GPR119MAP4K4HDAC1 | |
| SCHEMBL28388289 | 0.85 | CCR1 (0.45) | GPR119MAP4K4HDAC1 | |
| SCHEMBL28388288 | 0.85 | CCR1 (0.45) | GPR119MAP4K4HDAC1 | |
| SCHEMBL16627301 | 0.84 | GPR119 (0.50) | GPR119CHRM4AR | |
| SCHEMBL377605 | 0.83 | GPR119 (0.43) | GPR119MAP4K4HDAC1 | |
| SCHEMBL26128841 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4CHRM4HDAC1 | |
| SCHEMBL30286355 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4CHRM4HDAC1 | |
| SCHEMBL30546539 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4CHRM4HDAC1 | |
| SCHEMBL26125207 | 0.81 | MAP4K4 (0.58) | GPR119MAP4K4CHRM4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | GPR119 1966/4885MAP4K4 4069/4885CHRM4 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.